vedomostiregmedРегуляторные исследования и экспертиза лекарственных средствRegulatory Research and Medicine Evaluation3034-30623034-3453Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)vedomostiregmed-67Research ArticleФАРМАКОЭКОНОМИКАPHARMACOECONOMICSФармакоэкономика как инструмент клинической фармакологии для оптимизации фармакотерапии (обзор)Pharmacoeconomics as an instrument of clinical pharmacology for optimization of pharmacotherapy (review)РешетькоО. В.Reshet'koO. V.Reshetko@yandex.ruЛуцевичК. А.LutsevichK. A.noemail@neicon.ruГБОУ ВПО «Саратовский государственный медицинский университет им. В.И. Разумовского» Минздрава РоссииРоссияState Budgetary Educational Institution V.I. Razumovsky Saratov State Medical University of the Ministry of Health of the Russian FederationRussian Federation201513022018045457Copyright © Решетько О.В., Луцевич К.А., 20182018Решетько О.В., Луцевич К.А.Reshet'ko O.V., Lutsevich K.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.vedomostincesmp.ru/jour/article/view/67

Фармакоэкономика является важной составляющей в оценке медицинских технологий и экспертизы лекарственных средств для пациентов. Поскольку она является сравнительно молодой дисциплиной, ее методы продолжают развиваться. Фармакоэкономический анализ включает исследования «минимизации затрат», «затраты-эффективность», «затраты-утилитарность (полезность)» и «затраты-прибыль (польза)», предоставляя необходимую информацию, критическую для оптимизации фармакотерапии, оптимального размещения ресурсов здравоохранения и разработки новых лекарственных препаратов.

Pharmacoeconomics is an essential component of health technology assessment and the appraisal of medicines for use by patients. As a comparatively young discipline, its methods continue to evolve. Pharmacoeconomic analysis encompass cost-minimization, cost-utility, cost-benefit, and cost-effectiveness studies, providing essential information critical for optimization of pharmacotherapy, optimal healthcare resource allocation and drug development success.

pharmacoeconomicsanalysisclinical pharmacologyфармакоэкономикаанализклиническая фармакологияReferencesRitter JM. Money makes the world go round: the pervasiveness of pharmacoeconomics. Br J Clin Pharmacol. 2008; 66: 755-7.Ritter JM. Money makes the world go round: the pervasiveness of pharmacoeconomics. Br J Clin Pharmacol. 2008; 66: 755–7.Drummond M. Pharmacoeconomics: friend or foe? Ann Rheum Dis 2006; 65 (Suppl. III): iii44-iii47.Drummond M. Pharmacoeconomics: friend or foe? Ann Rheum Dis 2006; 65 (Suppl. III): iii44–iii47.Pang F. Design, analysis and presentation of multinational economic studies. The need for guidance. Pharmacoeconomics 2002; 20: 75-90.Pang F. Design, analysis and presentation of multinational economic studies. The need for guidance. Pharmacoeconomics 2002; 20: 75–90.Петров ВИ. Фармакоэпидемиология и фармакоэкономика в России: состояние проблемы и перспективы развития. Клинические исследования лекарств в России 2002; (1): 8-10.Petrov VI. Pharmacoepidemiology and pharmacoeconomics in Russia: the status of the problems and prospects of development. Klinicheskie issledovanija lekarstv v Rossii 2002; (1): 8-10 (in Russian).Edlin R, Round J, Hulme C, McCabe C. Cost effectiveness analysis and efficient use of the pharmaceutical budget: the key role of clinical pharmacologists. Br J Clin Pharmacol. 2010; 70: 350-355.Edlin R, Round J, Hulme C, McCabe C. Cost effectiveness analysis and efficient use of the pharmaceutical budget: the key role of clinical pharmacologists. Br J Clin Pharmacol. 2010; 70: 350–355.Mohan L, Kumari KM, Dikshit H, Biswas NR. Pharmacoeconomic exercise for undergraduate medical students. Int J Basic Clin Pharmacol. 2014; 3: 10991100.Mohan L, Kumari KM, Dikshit H, Biswas NR. Pharmacoeconomic exercise for undergraduate medical students. Int J Basic Clin Pharmacol. 2014; 3: 1099– 1100.Kulkarni U, Deshmukh YA, Moghe VV, Rege N, Kate M. Introducing pharmacoeconomics (PE) in medical undergraduate curriculum. Afr J Pharm Pharmacol. 2010; 4: 27-30.Kulkarni U, Deshmukh YA, Moghe VV, Rege N, Kate M. Introducing pharmacoeconomics (PE) in medical undergraduate curriculum. Afr J Pharm Pharmacol. 2010; 4: 27–30.Babar ZU, Scahill S. Is there a role for pharmacoeconomics in developing countries? Pharmacoeconomics 2010; 28: 1069-74.Babar ZU, Scahill S. Is there a role for pharmacoeconomics in developing countries? Pharmacoeconomics 2010; 28: 1069–74.Singh J. International society for pharmacoeconomics and outcomes research. Indian J Pharmacol. 2006; 38: 376-7.Singh J. International society for pharmacoeconomics and outcomes research. Indian J Pharmacol. 2006; 38: 376–7.Lyles A. Recent trends in pharmacoeconomics: Needs and unmet needs. Eur J Pharm Sci 2008; 34: S7-S24.Lyles A. Recent trends in pharmacoeconomics: Needs and unmet needs. Eur J Pharm Sci 2008; 34: S7-S24.Brazier J. Valuing health states for use in cost-effectiveness analysis. Pharmacoeconomics 2008; 26: 769-79.Brazier J. Valuing health states for use in cost-effectiveness analysis. Pharmacoeconomics 2008; 26: 769–79.Drummond M, Barbieri M, Cook J, Glick H, Lis J, Malik F, et al. Transferability of economic evaluations across jurisdictions: ISPOR good research practices task force report. Value Health 2009; (12): 409-18.Drummond M, Barbieri M, Cook J, Glick H, Lis J, Malik F, et al. Transferability of economic evaluations across jurisdictions: ISPOR good research practices task force report. Value Health 2009; (12): 409–18.Bodrogi J, Kalo Z. Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development. Br J Pharmacol. 2010; 159: 1367-73.Bodrogi J, Kalo Z. Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development. Br J Pharmacol. 2010; 159: 1367–73.Honig PK, Lalonde R. The economics of drug development: a grim reality and a role for clinical pharmacology. Clin Pharmacol Ther. 2010; 87: 247-51.Honig PK, Lalonde R. The economics of drug development: a grim reality and a role for clinical pharmacology. Clin Pharmacol Ther. 2010; 87: 247–51.Honig PK. Comparative effectiveness: The fourth hurdle in drug development and a role for clinical pharmacology. Clin Pharmacol Ther. 2011; 89: 151-6.Honig PK. Comparative effectiveness: The fourth hurdle in drug development and a role for clinical pharmacology. Clin Pharmacol Ther. 2011; 89: 151–6.Krammer H. Pharmacoeconomic analyses - chance or 4th hurdle for innovative drugs. Wien Med Wochenschr 2006; 156: 606-11.Krammer H. Pharmacoeconomic analyses – chance or 4th hurdle for innovative drugs. Wien Med Wochenschr 2006; 156: 606–11.Grabowski H, Vernon J, DiMasi JA. Returns on research and development for 1990s new drug introductions. Pharmacoeconomics 2002; 20 (Suppl. 3): 11 -29.Grabowski H, Vernon J, DiMasi JA. Returns on research and development for 1990s new drug introductions. Pharmacoeconomics 2002; 20 (Suppl. 3): 11–29.Robertson J, Lang D, Hill S. Use of pharmacoeconomics in prescribing research. Part 1: costs-moving beyond the acquisition price for drugs. J Clin Pharm Ther. 2003; 28: 73-9.Robertson J, Lang D, Hill S. Use of pharmacoeconomics in prescribing research. Part 1: costs-moving beyond the acquisition price for drugs. J Clin Pharm Ther. 2003; 28: 73–9.Newby D, Hill S. Use of pharmacoeconomics in prescribing research. Part 2: cost-minimization analysis - when are two therapies equal? J Clin Pharm Ther. 2003; 28: 145-50.Newby D, Hill S. Use of pharmacoeconomics in prescribing research. Part 2: cost- minimization analysis – when are two therapies equal? J Clin Pharm Ther. 2003; 28: 145–50.Lopert R, Lang DL, Hill S. Use of pharmacoeconomics in prescribing research. Part 3: Cost-effectiveness analysis - a technique for decision-making at the margin. J Clin Pharm Ther. 2003; 28: 243-9.Lopert R, Lang DL, Hill S. Use of pharmacoeconomics in prescribing research. Part 3: Cost-effectiveness analysis – a technique for decision-making at the margin. J Clin Pharm Ther. 2003; 28: 243–9.Brinsmead R, Hill S. Use of pharmacoeconomics in prescribing research. Part 4: is cost-utility analysis a useful tool? J Clin Pharm Ther. 2003; 28: 339-46.Brinsmead R, Hill S. Use of pharmacoeconomics in prescribing research. Part 4: is cost-utility analysis a useful tool? J Clin Pharm Ther. 2003; 28: 339–46.McCabe C, Dixon S. Testing the validity of cost-effectiveness models. Pharmacoeconomics 2000; 17: 501-13.McCabe C, Dixon S. Testing the validity of cost-effectiveness models. Pharmacoeconomics 2000; 17: 501–13.Khanna D, Tsevat J. Health-related Quality of Life - an introduction. Am J Managed Care 2007; 13: S218-S223.Khanna D, Tsevat J. Health-related Quality of Life – an introduction. Am J Managed Care 2007; 13: S218-S223.Vemer P, Rutten-van Molken MPMH. Largely ignored: the impact of the threshold value for a QALY on the importance of a transferability factor. Eur J Health Econ. 2011; 12: 397-404.Vemer P, Rutten-van Molken MPMH. Largely ignored: the impact of the threshold value for a QALY on the importance of a transferability factor. Eur J Health Econ. 2011; 12: 397–404.Hughes D. An agenda for UK clinical pharmacology. Pharmacoeconomics. Br J Clin Pharmacol. 2012; 73: 968-72.Hughes D. An agenda for UK clinical pharmacology. Pharmacoeconomics. Br J Clin Pharmacol. 2012; 73: 968–72.Hughes D, Reynolds DJ. Pharmacoeconomics: principles and relevance to the activities of drug and therapeutics committees. Clin Med. 2009; 9: 490-2.Hughes D, Reynolds DJ. Pharmacoeconomics: principles and relevance to the activities of drug and therapeutics committees. Clin Med. 2009; 9: 490–2.Rohilla A, Kumar A, Keshari R, et al. Pharmacoeconomics: An overview. International Journal of Research in Pharmacy and Chemistry 2013; 3: 64-8.Rohilla A, Kumar A, Keshari R, et al. Pharmacoeconomics: An overview. International Journal of Research in Pharmacy and Chemistry 2013; 3: 64–8.Waldman SA, Terzic A. Pharmacoeconomics in the era of individualized medicine. Clin Pharmacol Ther. 2008; 84: 179-82.Waldman SA, Terzic A. Pharmacoeconomics in the era of individualized medicine. Clin Pharmacol Ther. 2008; 84: 179–82.Iram M, Rani S, Hiremath R. Pharmacoeconomics: Need for the day. Indian J Pharm Pract. 2009; 2: 16-18.Iram M, Rani S, Hiremath R. Pharmacoeconomics: Need for the day. Indian J Pharm Pract. 2009; 2: 16–18.Vegter S, Boersma C, Rozenbaum M, Wilffert B, Navis GJ, Postma MJ. Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines. Pharmacoeconomics 2008; 26: 569-87.Vegter S, Boersma C, Rozenbaum M, Wilffert B, Navis GJ, Postma MJ. Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines. Pharmacoeconomics 2008; 26: 569–87.Петров ВИ, Сабанов АВ. Фармакоэкономические исследования в Российской системе здравоохранения. Клинические исследования лекарственных средств в России 2004; (1): 7.Petrov VI, Sabanov AV. Pharmacoeconomic studies in the Russian health care system. Klinicheskie issledovanija lekarstv v Rossii 2004; (1): 7 (in Russian).

The authors declare that there are no conflicts of interest present.